Results 31 to 40 of about 349 (107)

Adaptations of glucagon‐like peptide‐1 receptor agonist‐induced weight loss, drivers of weight regain and future directions of therapeutics

The Journal of Physiology, EarlyView.
Abstract figure legend During GLP‐1RA treatment reduced appetite and energy intake, delayed gastric emptying, decreased visceral fat mass and improved glycaemic control contribute to weight loss. After treatment cessation these benefits are partially or completely reversed, resulting in weight regain, accompanied by increased appetite and energy intake,
Camille E. M. Piguet, Rosie Nucci, Jacqueline L. Beaudry   +2 more
wiley   +1 more source

Combination Pharmacotherapies for Obesity—Current Evidence and Future Directions

Endocrinology, Diabetes &Metabolism, Volume 9, Issue 5, September 2026.
Combination pharmacotherapy for obesity can enhance weight loss by targeting complementary neuroendocrine and metabolic pathways. Such benefits are largely additive but limited by tolerability, cost and access. This review outlines practical clinical archetypes and a research agenda for safer, more precise and durable combination strategies across ...
A. B. M. Kamrul‐Hasan, Arnav Kalra, Nitin Kapoor, Deep Dutta, Kunal Mahajan, Robin Maskey, Syed Abbas Raza   +6 more
wiley   +1 more source

Glucagon‐Like Peptide‐1 Receptor Agonist‐Based Agents and Body Composition: Filling More Gaps

Obesity, Volume 34, Issue S2, Page 51-63, September 2026.
ABSTRACT The last 2 decades have seen historic advances in the treatment of obesity. We are entering an era of defining obesity not by weight‐based outcomes but by changes in body composition. Glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) are forming the platform for obesity treatments based on their high level of efficacy. Body composition can
Robert L. Dubin, Tierra N. Sanders, Hunter M. Schwab, Steven B. Heymsfield, Frank L. Greenway   +4 more
wiley   +1 more source

Perspectivas innovadoras en el tratamiento de la obesidad

Revista de la Sociedad Argentina de Diabetes
El tratamiento de la obesidad atraviesa un cambio paradigmático impulsado por el desarrollo de terapias hormonales estimuladas por nutrientes, por la eficacia en la reducción del peso (15-25%) que se aproxima a la obtenida con la cirugía bariátrica, y ...
María Yuma
doaj   +1 more source

Positioning Incretin‐Based and Next‐Generation Obesity Management Medications: A Methodological Framework for a Series of Systematic Reviews and Network Meta‐Analyses

Diabetes, Obesity and Metabolism, Volume 28, Issue 9, Page 7768-7778, September 2026.
ABSTRACT Background The obesity pharmacotherapy landscape is evolving rapidly, with several approved incretin‐based therapies and an expanding pipeline of investigational compounds targeting multiple metabolic pathways. Conventional evidence syntheses often struggle to accommodate differences in dose selection, treatment duration and stage of clinical ...
Matteo Monami, Benedetta Ragghianti, Edoardo Mannucci   +2 more
wiley   +1 more source

Futuro en la diabetes: innovaciones terapéuticas y nuevas moléculas

Revista de la Sociedad Argentina de Diabetes
Exploraremos cuáles son los desafíos más importantes en el tratamiento de la diabetes mellitus (DM). Inicialmente el abordaje terapéutico de la DM fue neutralizar el impacto de las complicaciones crónicas (CC) dado que el diagnóstico era muy tardío ...
León E. Litwak
doaj   +1 more source

Impact of Sleeve Gastrectomy Versus Intensive Lifestyle Modifications With Obesity Management Medications on BMI Trajectory and Target Attainment: A Prospective Matched Cohort Study

Diabetes, Obesity and Metabolism, Volume 28, Issue 8, Page 7126-7136, August 2026.
ABSTRACT Aims To compare sleeve gastrectomy (SG) with intensive lifestyle modification combined with obesity management medications (ILM/OMMs) in adults with severe obesity, focusing on BMI trajectory, time to achieving clinically meaningful weight loss, and metabolic outcomes in a real‐world clinical setting.
Maria Francesca Russo, Giovanni Casella, Giulia Angelini, Sara Russo, James Casella‐Mariolo, Vito D'Andrea, Giulio Illuminati, Lidia Castagneto‐Gissey   +7 more
wiley   +1 more source

Mechanotransduction of Collagen Biostimulators: Comparative Signaling and Implications for GLP‐1 RA–Associated Facial Aging

Journal of Cosmetic Dermatology, Volume 25, Issue 8, August 2026.
ABSTRACT Background GLP‐1 receptor agonists (GLP‐1 RAs) can induce rapid weight reduction, often associated with facial volume loss. However, optimal regenerative strategies remain unclear. Aims To compare the mechanotransduction profiles of the major injectable collagen biostimulator classes in GLP‐1 RA–induced facial aging.
Chang‐Hwan Cho, Atsuko Yanagawa, Beomjoon Kim   +2 more
wiley   +1 more source

Mitochondrial Adaptations in Skeletal Muscle Following Incretin‐Based Therapies: In Vitro

Journal of Cachexia, Sarcopenia and Muscle, Volume 17, Issue 2, April 2026.
ABSTRACT Background Incretin‐based therapies such as glucagon‐like peptide‐1 receptor agonists (GLP‐1Ras), dual GLP‐1/GIP agonists and amylin analogues have demonstrated significant weight loss benefits. However, their impact on skeletal muscle mitochondrial function, particularly under metabolic stress, remains unclear. This study aimed to investigate
Victoria Old, Melanie Davies, Matthew Denniff, Pratik Choudhary, Nicholas Eastley, Robert U. Ashford, Emma Watson   +6 more
wiley   +1 more source

Recent advances in peptide-based therapies for obesity and type 2 diabetes [PDF]

Options for the treatment of type 2 diabetes mellitus (T2DM) and obesity have recently been expanded by the results of several large clinical trials with incretin-based peptide therapies.
Flatt, Peter R, Conlon, J Michael, Bailey, Clifford J   +2 more
core   +1 more source